These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29215098)

  • 1. Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial.
    Van Cutsem E; Falcone A; Garcia-Carbonero R; Komatsu Y; Pastorino A; Peeters M; Shimada Y; Yamazaki K; Yoshino T; Zaniboni A; Amellal N; Kanehisa A; Winkler R; Makris L; Mayer RJ; Ohtsu A; Tabernero J
    ESMO Open; 2017; 2(5):e000261. PubMed ID: 29215098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer.
    Tabernero J; Van Cutsem E; Ohtsu A; Amellal N; Cadour S; Fougeray R; Haffemayer B; Mayer RJ
    ESMO Open; 2017; 2(5):e000284. PubMed ID: 29211817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study.
    Bachet JB; Wyrwicz L; Price T; Cremolini C; Phelip JM; Portales F; Ozet A; Cicin I; Atlan D; Becquart M; Vidot L; Mounedji N; Van Cutsem E; Taieb J; Falcone A
    ESMO Open; 2020 Jun; 5(3):e000698. PubMed ID: 32487542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis.
    Tabernero J; Argiles G; Sobrero AF; Borg C; Ohtsu A; Mayer RJ; Vidot L; Moreno Vera SR; Van Cutsem E
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS.
    Tabernero J; Alsina M; Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Ando T; Yalçın Ş; Van Cutsem E; Sabater J; Skanji D; Leger C; Amellal N; Ilson DH
    Gastric Cancer; 2020 Jul; 23(4):689-698. PubMed ID: 32128634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Alsina M; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Hosokawa A; Yalçın Ş; Fujitani K; Beretta GD; Cutsem EV; Winkler RE; Makris L; Ilson DH; Tabernero J
    Lancet Oncol; 2018 Nov; 19(11):1437-1448. PubMed ID: 30355453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer.
    Marques D; Costa AL; Mansinho A; Quintela A; Pratas E; Brito-da-Silva J; Cruz J; Félix J; Rodrigues J; Mota M; Teixeira AR; Dâmaso S; Pinheiro S; Andreozzi V; Costa L; Barros AG
    Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):665-672. PubMed ID: 37487914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
    Van Cutsem E; Hochster H; Shitara K; Mayer R; Ohtsu A; Falcone A; Yoshino T; Doi T; Ilson DH; Arkenau HT; George B; Benhadji KA; Makris L; Tabernero J
    ESMO Open; 2022 Dec; 7(6):100633. PubMed ID: 36455504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated safety summary for trifluridine/tipiracil (TAS-102).
    Falcone A; Ohtsu A; Van Cutsem E; Mayer RJ; Buscaglia M; Bendell JC; Kopetz S; Bebeau P; Yoshino T
    Anticancer Drugs; 2018 Jan; 29(1):89-96. PubMed ID: 29176395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
    Kwakman JJM; Vink G; Vestjens JH; Beerepoot LV; de Groot JW; Jansen RL; Opdam FL; Boot H; Creemers GJ; van Rooijen JM; Los M; Vulink AJE; Schut H; van Meerten E; Baars A; Hamberg P; Kapiteijn E; Sommeijer DW; Punt CJA; Koopman M
    Int J Clin Oncol; 2018 Jun; 23(3):482-489. PubMed ID: 29204933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
    Bullement A; Underhill S; Fougeray R; Hatswell AJ
    Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
    Longo-Muñoz F; Argiles G; Tabernero J; Cervantes A; Gravalos C; Pericay C; Gil-Calle S; Mizuguchi H; Carrato-Mena A; Limón ML; Garcia-Carbonero R
    Clin Transl Oncol; 2017 Feb; 19(2):227-235. PubMed ID: 27443414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2017 Jun; 16(2):85-92. PubMed ID: 28242161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
    Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A;
    Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).
    Shitara K; George B; Taieb J; Sundar R; Fakih MG; Makris L; Benhadji KA; Ghidini M
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9361-9374. PubMed ID: 37213030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer.
    Kang C; Dhillon S; Deeks ED
    Drugs; 2019 Sep; 79(14):1583-1590. PubMed ID: 31489588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.
    Xu J; Kim TW; Shen L; Sriuranpong V; Pan H; Xu R; Guo W; Han SW; Liu T; Park YS; Shi C; Bai Y; Bi F; Ahn JB; Qin S; Li Q; Wu C; Ma D; Lin D; Li J
    J Clin Oncol; 2018 Feb; 36(4):350-358. PubMed ID: 29215955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
    Argilés G; André T; Hollebecque A; Calvo A; Dahan L; Cervantes A; Leger C; Amellal N; Fougeray R; Tabernero J
    Eur J Cancer; 2019 May; 112():12-19. PubMed ID: 30889492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data.
    Fernández Montes A; Carmona-Bayonas A; Jimenez-Fonseca P; Vázquez Rivera F; Martinez Lago N; Covela Rúa M; Cousillas Castiñeiras A; Gonzalez Villarroel P; De la Cámara Gómez J; Méndez JCM; Carriles Fernández C; Sanchez Cánovas M; Garcia García T
    Sci Rep; 2021 Jul; 11(1):14321. PubMed ID: 34253805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.
    Mayer RJ; Hochster HS; Cohen SJ; Winkler R; Makris L; Grothey A
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):961-969. PubMed ID: 30350179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.